Ahmed A. Suleiman

ORCID: 0000-0001-8499-6316 · 2 papers in corpus

other 2021

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Clinical and translational science ·doi:10.1111/cts.13040

Elagolix is a novel, oral gonadotropin-releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent wit…

nonrandomized-trial 2020

Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain

CPT: pharmacometrics & systems pharmacology ·doi:10.1002/psp4.12560

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose-dependent manner. It is indicated for management of moderate-to-severe pain associated with endometriosis. A population expos…